This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

About KEYTRUDA®▼ (pembrolizumab)

Updated on 15/03/2018

ONCOLOGY
Unlock the potential of KEYTRUDA® (pembrolizumab)

Metastatic NSCLC - first line indication

KEYTRUDA as monotherapy is indicated for the first-line treatment of metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express PD-L1 with a ≥50% tumour proportion score (TPS) with no EGFR or ALK positive tumour mutations.

Advanced NSCLC - previously treated indication

KEYTRUDA as monotherapy is indicated for the treatment of locally advanced or metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express PD-L1 with a ≥1% TPS and who have received at least one prior chemotherapy regimen. Patients with EGFR or ALK positive tumour mutations should also have received targeted therapy before receiving KEYTRUDA.

For more information on KEYTRUDA in advanced NSCLC please click here

Advanced Melanoma indication

KEYTRUDA as monotherapy is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults.

For more information on KEYTRUDA in advanced Melanoma please click here

Advanced Urothelial Carcinoma

KEYTRUDA as monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy. KEYTRUDA as monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin-containing chemotherapy.

The licensed dose of KEYTRUDA varies based on indication:

  • 200 mg by intravenous infusion over 30 minutes every 3 weeks for metastatic NSCLC that has not been previously treated (first line) with chemotherapy for cHL or for urothelial carcinoma.
  • 2 mg/kg by intravenous infusion over 30 minutes every 3 weeks for advanced NSCLC that has been previously treated with chemotherapy or for advanced melanoma.

ALK: Anaplastic lymphoma kinase; EGFR: Epidermal growth factor receptor.

Please refer to the KEYTRUDA Summary of Product Characteristics and Risk Minimisation Materials before prescribing KEYTRUDA. Risk Minimisation Materials are available online, from your MSD representative or from MSD Medical Information (Email: medicalinformationuk@merck.com, Phone: 01992 467 272).

For more information on KEYTRUDA in advanced Urothelial Carcinoma please click here

KEYTRUDA exerts dual ligand blockade

KEYTRUDA is a selective monoclonal antibody that blocks the programmed cell death-1 (PD-1) protein pathway, potentiating T-cell responses, including anti-tumour responses.1,2

When functioning properly, T cells are activated and can attack tumour cells1,2

Some tumours can evade the immune system through the PD-1 pathway. On the surface of tumour cells the dual PD-1 ligands, PD-L1 and PD-L2, bind to the PD-1 receptors on T cells to inactivate them, allowing tumour cells to evade detection1,2

By inhibiting this process, KEYTRUDA reactivates tumour-specific cytotoxic T lymphocytes and anti-tumour immunity1,2

PD-1: Programmed cell death-1; PD-L1: Programmed cell death ligand-1; PD-L2: Programmed cell death ligand-2.

Useful links

Melanoma NICE Guidance: Pembrolizumab for advanced melanoma not previously treated with ipilimumab

Melanoma NICE Guidance: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab

KEYNOTE 10 Electronic Reprint, KEYTRUDA

References

  1. Harvey, RD. Clin Pharm Therapeutics 2014:92(2):214-223.
  2. KEYTRUDA Summary of Product Characteristics.

Supporting documentation

Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

ONCO-1246426-0000 | Date of Preparation: March 2018